BARRY A. BUNIN
CEO
Collaborative Drug Discovery
USA
Biography
Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen $50 million in business transactions over the last two decades. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Dr. Bunin is on a patent for Kyprolis™ (Carfilzomib for Injection) — a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as the centerpiece of Amgen’s $10.4 Billion acquisition of Onyx Pharmaceuticals.
Research Interest
Research Interest: Interaction with FDA. Development of generic and branded regulatory strategic plans for new product development, life cycle management of marketed products. Evaluation of potential products & in-licensing opportunities. Participate in all aspects of clinical development & study management, providing scientific, medical, and logistical direction and support to studies.Clinical development in CNS/Pain Managing Phase 2-4 clinical trials